JRCT ID: jRCT2031230002
Registered date:02/04/2023
A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumors
Basic Information
Recruitment status | Recruiting |
---|---|
Health condition(s) or Problem(s) studied | Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms |
Date of first enrollment | 02/04/2023 |
Target sample size | 417 |
Countries of recruitment | US,Japan,Australia,Japan,South Korea,Japan,China,Japan,France,Japan,Spain,Japan,Italia,Japan |
Study type | Interventional |
Intervention(s) | Module 1 AZD9592 Monotherapy Drug: AZD9592 Varying doses of AZD9592 Module 2 AZD9592 Combination with Osimertinib Drug: AZD9592 Varying doses of AZD9592 Drug: Osimertinib tablets administered orally Module 3 AZD9592 Combination 5-FU, Bevacizumab, Leucovorin Module 3 has two parts: Part A aims to determine the safety, tolerability and/or recommended phase 2 dose (RP2D) of AZD9592 in combination with 5-FU, Bevacizumab, Leucovorin in Colorectal Cancer (CRC) Part B aims to determine the safety, tolerability and evaluate anti-tumor activity of AZD9592 in combination with 5-FU, Bevacizumab, Leucovorin in Colorectal Cancer (CRC) |
Outcome(s)
Primary Outcome | 1. Incidence of Adverse Events (AEs) [ Time Frame: From time of Informed Consent to 30 days post last dose of AZD9592 ] Number of patients with adverse events by system organ class and preferred term 2. Incidence of Serious Adverse Events (SAEs) [ Time Frame: From time of Informed Consent to 30 days post last dose of AZD9592 ] Number of patients with serious adverse events by system organ class and preferred term 3. Incidence of dose-limiting toxicities (DLT) as defined in the protocol [ Time Frame: From time of first dose of AZD9592 to end of DLT period (approximately 21 days) ] Number of patients with at least 1 dose-limiting toxicity (DLT), which is any toxicity defined as a DLT in the Clinical Study Protocol 4. Incidence of baseline laboratory finding, ECG and vital signs changes [ Time Frame: From time of Informed Consent to 30 days post last dose of AZD9592 ] measured by laboratory and vital sign variables over time including change from baseline 5. Proportion of patients with radiological response (ORR) [ Time Frame: From date of first dose of AZD9592 up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years) ] Assessed by overall response rate (ORR) defined as the proportion of patients who have a confirmed complete or partial radiological response by the Investigator according to RECIST v1.1 (for patients in the dose expansion cohorts, only) |
---|---|
Secondary Outcome |
Key inclusion & exclusion criteria
Age minimum | >= 18age old |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | - Age 18 years or more - Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1 - Life expectancy 12 weeks or more - Measurable disease per RECIST v1.1 - Adequate organ and marrow function as defined in the protocol Additional Inclusion Criteria for Module 1: - Histologically or cytologically confirmed metastatic or locally advanced EGFRmut., NSCLC; metastatic EGFRwt. NSCLC; recurrent or metastatic HNSCC of the oral cavity; metastatic CRC. Additional Inclusion Criteria for Module 2: - Histologically or cytologically confirmed metastatic NSCLC EGFRmut. Additional Inclusion Criteria for Module 3: - Histologically or cytologically confirmed metastatic CRC. |
Exclude criteria | - History of (non-infectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening. - Spinal cord compression or a history of leptomeningeal carcinomatosis. - Active infection including tuberculosis and HBV, HCV or HIV - Brain metastases unless treated (prior treatment required only for Module 1), asymptomatic, stable, and not requiring continuous corticosteroids at a dose of > 10 mg prednisone/day or equivalent for at least 4 weeks prior to start of study treatment. - Participants with cardiac comorbidities as defined in the study protocol |
Related Information
Primary Sponsor | Hibi Kazushige |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) | NCT05647122 |
Contact
Public contact | |
Name | Kazushige Hibi |
Address | 3-1, Ofuka-cho, Kita-ku, Osaka-shi, Osaka Osaka Japan 530-0011 |
Telephone | +81-6-4802-3533 |
RD-clinical-information-Japan@astrazeneca.com | |
Affiliation | Astrazeneka K.K |
Scientific contact | |
Name | Kazushige Hibi |
Address | 3-1, Ofuka-cho, Kita-ku, Osaka-shi, Osaka Osaka Japan 530-0011 |
Telephone | +81-6-4802-3533 |
RD-clinical-information-Japan@astrazeneca.com | |
Affiliation | Astrazeneka K.K |